Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled study of ralinepag in pulmonary arterial hypertension
MOH_2019-06-30_004797Phase 3Active, not recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Placebo + background therapy with Ralinepag + background therapy (2 arms). Primary endpoint: Disease progression and satisfactory clinical response. Started Mar 2019; status: active, not recruiting.
02
Drugs
ralinepag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2019-06-30_004797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-06-30_004797.